Contents:

Analgesics in Belgium Euromonitor International March 2009 List of Contents and Tables Executive Summary Disappointing Results in 2008 After Strong Growth in 2007 Manufacturers Focus on Leading Brands in Restrictive Environment Market Still Fragmented, Despite Growing Global Consolidation Pharmacies Still Monopolise Distribution, Despite Beginning of Deregulation Rather Bleak Outlook in the Short Term Key Trends and Developments Bleak Prospects for Economy, Policy and Thus Purchasing Power A More Favourable Environment for OTC Healthcare Despite Continuing Conservatism Mixed Results for Segmentation Consumer Lifestyles Impact OTC Formats Related Markets Increasingly Overlap With OTC Beginning of Deregulation and the Emergence of Internet Sales, But No Real Change in the Dominance of Chemists/pharmacies Less Room To Manoeuvre for Smaller Players Market Indicators Table 1 Consumer Expenditure on Health Goods and Medical Services 2003-2008 Table 2 Life Expectancy at Birth 2003-2008 Market Data Table 3 Sales of OTC Healthcare by Sector: Value 2003-2008 Table 4 Sales of OTC Healthcare by Sector: % Value Growth 2003-2008 Table 5 OTC Healthcare Company Shares by Value 2004-2008 Table 6 OTC Healthcare Brand Shares by Value 2005-2008 Table 7 Penetration of Private Label by Sector 2003-2008 Table 8 Sales of OTC Healthcare by Distribution Format: % Analysis 2003-2008 Table 9 Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2008 Table 10 Forecast Sales of OTC Healthcare by Sector: Value 2008-2013 Table 11 Forecast Sales of OTC Healthcare by Sector: % Value Growth 2008-2013 Appendix OTC Registration and Classification De-listing Or De-reimbursement Advertising Packaging and Labelling Distribution Vitamins and Dietary Supplements Registration and Classification EU Legislation Self-medication and Preventative Medicine the Role Played by the Belgian Government Trend Reversal Over the 2006-2008 Period Alternative Therapy Lobbying and Consumer Loyalty Ensure the Ongoing Success of Homeopathy Other Alternative Therapies Impacted by Fashion Generics Switches Definitions Sources Summary 1 Research Sources Biodiphar NV SA Strategic Direction Key Facts Summary 2 Biodiphar SA: Key Facts Summary 3 Biodiphar SA: Operational Indicators Company Background and Production Competitive Positioning Summary 4 Biodiphar SA: Competitive Position 2008 Omega Pharma NV Strategic Direction Key Facts Summary 5 Omega Pharma NV: Key Facts Summary 6 Omega Pharma NV: Operational Indicators Company Background Production Summary 7 Omega Pharma NV: Production Statistics 2005 Competitive Positioning Summary 8 Omega Pharma NV: Competitive Position 2008 Patch Pharma SA Strategic Direction Key Facts Summary 9 Patch Pharma NV SA: Key Facts Company Background and Production Competitive Positioning Pharmaceutiques Trenker, Laboratoires Strategic Direction Key Facts Summary 10 Pharmaceutiques Trenker, Laboratoires: Key Facts Summary 11 Pharmaceutiques Trenker, Laboratoires: Operational Indicators Company Background and Production Competitive Positioning Summary 12 Pharmaceutiques Trenker, Laboratoires: Competitive Position 2008 Vemedia Pharma NV Strategic Direction Key Facts Summary 13 Vemedia Pharma NV: Key Facts Company Background Production Summary 14 Vemedia Pharma NV: Production Statistics 2008 Competitive Positioning Summary 15 Vemedia Pharma NV: Competitive Position 2008 Headlines Trends Switches Competitive Landscape Prospects Sector Data Table 12 Sales of Analgesics by Subsector: Value 2003-2008 Table 13 Sales of Analgesics by Subsector: % Value Growth 2003-2008 Table 14 Herbal vs Standard Topical Analgesics 2003-2008 Table 15 Topical Analgesics by Format: % Value Breakdown 2004-2008 Table 16 Analgesics Company Shares by Value 2004-2008 Table 17 Analgesics Brand Shares by Value 2005-2008 Table 18 Forecast Sales of Analgesics by Subsector: Value 2008-2013 Table 19 Forecast Sales of Analgesics by Subsector: % Value Growth 2008-2013